Liza Yambay Valiente, MD
Endocrinology, Diabetes & Metabolism · Normal, ILNPI 1881840080
Payments from drug & device makers
Across 59 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$206
- Sanofi-aventis U.S. LLC$152
- Dompe US, Inc.$148
- Novo Nordisk$141
- Abbott$130
- AstraZeneca$113
- plus $246 from 8 others
What the payments were for
- Food & beverage$1,135100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 11 | $206 |
| Sanofi-aventis U.S. LLC | 9 | $152 |
| Dompe US, Inc. | 1 | $148 |
| Novo Nordisk | 7 | $141 |
| Abbott | 10 | $130 |
| AstraZeneca | 6 | $113 |
| Medtronic(2 entities) | 4 | $63 |
| Boehringer Ingelheim | 2 | $44 |
| Tandem Diabetes Care, Inc. | 2 | $41 |
| Lilly USA, LLC | 3 | $38 |
| Dexcom, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$148
How this compares
$1,135 in reported general payments places this provider in the 55th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 232 | $382,522 |
| MounjaroTirzepatide | 151 | $221,200 |
| JardianceEmpagliflozin | 130 | $148,640 |
| FarxigaDapagliflozin Propanediol | 147 | $144,140 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $108,387 |
| TrulicityDulaglutide | 71 | $102,591 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $67,125 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $53,479 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $50,535 |
| RybelsusSemaglutide | 34 | $49,227 |
| Tresiba Flextouch U-100Insulin Degludec | 43 | $25,650 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $20,494 |
| TradjentaLinagliptin | 17 | $17,792 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $17,224 |
| Humalog Kwikpen U-100Insulin Lispro | 47 | $17,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $141 | $438,982285 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $38 | $336,116253 claims |
| Boehringer IngelheimJardiance, Tradjenta | $44 | $166,432147 claims |
| AstraZenecaFarxiga | $113 | $144,140147 claims |
| MerckJanuvia | $15 | $11,99915 claims |
| AbbVieSynthroid | $14 | $10,977147 claims |
| Sanofi-aventis U.S. LLCLantus | $152 | $4,11234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Normal
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
- Babak PazookiJoliet$582K
- Silvana PannainChicago$575K
- Ammar BayrakdarEvergreen Park$517K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.